EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 582 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Why the Fear of Cancer Recurrence Is Often Misunderstood and How... December 6, 2022 EMA Recommends Granting Marketing Authorisation for Generic Abiraterone Acetate May 4, 2021 Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical... April 6, 2023 How a Musician Copes With Life With Metastatic Breast Cancer March 17, 2021 Load more HOT NEWS After Misdiagnosis, Mom Found Out She Had Terminal Breast Cancer Shortly... Reflecting On My Time As the Cancer.Net Editor in Chief Coping With the Difficult Times of Cancer Survivorship Through My “Bucket... Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond...
